Shares of IXICO plc (LON:IXI – Get Free Report) shot up 13.5% during trading on Tuesday . The company traded as high as GBX 9.50 and last traded at GBX 9.22. 428,679 shares changed hands during mid-day trading, an increase of 245% from the average daily volume of 124,079 shares. The stock had previously closed at GBX 8.12.
IXICO Trading Up 13.5%
The business’s 50-day moving average is GBX 7.98 and its two-hundred day moving average is GBX 8.83. The company has a current ratio of 2.83, a quick ratio of 4.90 and a debt-to-equity ratio of 5.22. The stock has a market capitalization of £20.11 million, a PE ratio of -4.73, a PEG ratio of -0.38 and a beta of 0.13.
IXICO (LON:IXI – Get Free Report) last released its quarterly earnings data on Tuesday, May 19th. The company reported GBX (1.21) EPS for the quarter. The company had revenue of GBX 395 million during the quarter. IXICO had a negative net margin of 24.98% and a negative return on equity of 16.18%. On average, analysts predict that IXICO plc will post -289.3584879 earnings per share for the current year.
About IXICO
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.
Featured Stories
- Five stocks we like better than IXICO
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for IXICO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IXICO and related companies with MarketBeat.com's FREE daily email newsletter.
